Last updated: 2026-10-13 16:18:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Ironwood Pharmaceuticals, Inc. - (IRWD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.66, with a market capitalisation of $631.22M and a P/E ratio of 4.78. Over the past 52 weeks, its price has ranged from $1.41 to $5.78. This page covers its latest market performance, valuation, price trends and company information.
$631.22M | |
$3.74 | |
$21.20 | |
$0.53 | |
$3.76 | |
744.54K | |
1.98M | |
4.78 | |
$5.78 | |
$1.41 | |
-- | |
-- |
Ironwood Pharmaceuticals, Inc. - (IRWD) is currently trading at $3.66 as of 2026-10-13 16:17:00, down 2.79% ($0.10) from the previous close of $3.76
During today's regular trading session, IRWD has traded between $0.53 and $21.20, with a trading volume of 744.54K shares. The current price is near the lower end of today's range.
Over the past seven days, Ironwood Pharmaceuticals, Inc. - (IRWD) moved from $3.64 to $3.66, representing a gain of 0.41% ($0.01).
The stock traded between $3.54 and $3.97 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 2.00 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 51.4%
IRWD is currently trading at $3.66, placing it 51.4% of the way from its 52-week low of $1.41 to its 52-week high of $5.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ironwood Pharmaceuticals, Inc. - (IRWD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.